Detecting patients with Alzheimer's disease suitable for drug treatment: comparison of three methods of assessment
- PMID: 8312036
- PMCID: PMC1238759
Detecting patients with Alzheimer's disease suitable for drug treatment: comparison of three methods of assessment
Abstract
Background: Therapy to enhance cholinergic function in the brain is under evaluation for the treatment of Alzheimer's disease. Tetrahydroaminoacridine (tacrine) has recently received a product licence in the United States of America for the treatment of Alzheimer's disease, and the licence application in the United Kingdom will shortly be reviewed. It is therefore possible that this drug will become available for use in the UK in due course. There will then be a need for screening procedures for a large number of elderly patients to decide whether or not they have dementia and, if so, whether it is the result of Alzheimer's disease and is suitable for treatment with the new drug.
Method: A total of 246 patients aged 75 years or over in two general practices in Bristol were assessed to investigate the potential workload such screening would engender. Three different assessment schedules for the diagnosis of dementia were compared--the mini-mental state examination, the Kew test, and the abbreviated mental test score.
Results: None of the assessment schedules was found to be particularly onerous, with median times for administration of five, three and two minutes, respectively. A score of 23 or less on the mini-mental state examination was taken as the main cut-off point for further evaluation. Sixty six patients obtained this score--in 25 the low score reflected factors other than dementia, and 11 others declined further assessment. Of the remaining 30 patients only four had probable Alzheimer's disease at an appropriate level of severity for treatment, and lived with a carer who could ensure compliance and monitor side effects. Two of these patients were receiving conflicting medical treatment and a third declined therapy, leaving only one person for whom treatment could be prescribed.
Conclusion: It seems likely that of those medically suitable for treatment, it may not be possible to prescribe tacrine for an appreciable proportion. Nevertheless, all potential patients should be screened as the procedures involved are not onerous and at least some of those found suitable for treatment are likely to benefit from this new approach.
Comment in
-
Screening patients for Alzheimer's disease.Br J Gen Pract. 1994 Jun;44(383):283. Br J Gen Pract. 1994. PMID: 8037988 Free PMC article. No abstract available.
Similar articles
-
[Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].Encephale. 2003 May-Jun;29(3 Pt 1):266-72. Encephale. 2003. PMID: 12876552 French.
-
Maximizing function in Alzheimer's disease: what role for tacrine?Am Fam Physician. 1996 Aug;54(2):645-52. Am Fam Physician. 1996. PMID: 8701842
-
The pharmacological effects of ginkgo biloba, a plant extract, on the brain of dementia patients in comparison with tacrine.Psychopharmacol Bull. 1998;34(3):391-7. Psychopharmacol Bull. 1998. PMID: 9803773 Clinical Trial.
-
[Geriatric medicine in future].Nihon Ronen Igakkai Zasshi. 1989 Jan;26(1):1-10. Nihon Ronen Igakkai Zasshi. 1989. PMID: 2671448 Review. Japanese.
-
[New conception of Alzheimer's disease and the strategy for preclinical therapy].Nihon Rinsho. 2011 Dec;69 Suppl 10 Pt 2:252-6. Nihon Rinsho. 2011. PMID: 22755193 Review. Japanese. No abstract available.
Cited by
-
North of England evidence based guidelines development project: guideline for the primary care management of dementia.BMJ. 1998 Sep 19;317(7161):802-8. doi: 10.1136/bmj.317.7161.802. BMJ. 1998. PMID: 9740574 Free PMC article. Review. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical